| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80053 |
Comprehensive metabolic panel |
5,394 |
4,601 |
$161K |
| 87428 |
|
2,580 |
2,466 |
$150K |
| 70450 |
Computed tomography, head or brain; without contrast material |
593 |
536 |
$80K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,421 |
3,156 |
$75K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
5,748 |
5,428 |
$65K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,230 |
5,944 |
$60K |
| 36415 |
Collection of venous blood by venipuncture |
3,506 |
2,674 |
$49K |
| 80050 |
General health panel |
1,193 |
1,106 |
$45K |
| 84484 |
|
1,539 |
1,248 |
$44K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
856 |
454 |
$40K |
| 71046 |
Radiologic examination, chest; 2 views |
2,016 |
1,811 |
$37K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,687 |
1,388 |
$33K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
949 |
916 |
$32K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
514 |
485 |
$23K |
| 71045 |
Radiologic examination, chest; single view |
1,892 |
1,665 |
$21K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,443 |
2,080 |
$21K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
124 |
112 |
$20K |
| 80061 |
Lipid panel |
1,647 |
1,562 |
$15K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
602 |
563 |
$12K |
| 83880 |
|
632 |
534 |
$12K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
419 |
306 |
$11K |
| 83690 |
|
764 |
675 |
$10K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,446 |
1,396 |
$10K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
196 |
48 |
$10K |
| 80306 |
|
489 |
427 |
$9K |
| 87400 |
|
711 |
684 |
$9K |
| 84443 |
Thyroid stimulating hormone (TSH) |
988 |
937 |
$8K |
| 87081 |
|
909 |
852 |
$8K |
| 81003 |
|
2,429 |
2,215 |
$8K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
113 |
77 |
$8K |
| 81025 |
|
948 |
868 |
$8K |
| 87807 |
|
613 |
587 |
$7K |
| 81001 |
|
1,696 |
1,525 |
$7K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
863 |
780 |
$6K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
604 |
484 |
$5K |
| 83605 |
|
233 |
202 |
$5K |
| 83735 |
|
552 |
469 |
$4K |
| 85610 |
|
1,246 |
924 |
$4K |
| 87077 |
|
503 |
441 |
$4K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
44 |
44 |
$3K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
54 |
53 |
$3K |
| 84439 |
|
430 |
370 |
$2K |
| 71020 |
|
160 |
148 |
$2K |
| 87186 |
|
446 |
398 |
$2K |
| 81002 |
|
595 |
558 |
$2K |
| 87070 |
|
114 |
105 |
$2K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
21 |
20 |
$2K |
| 87430 |
|
162 |
154 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
493 |
424 |
$2K |
| 85730 |
|
171 |
162 |
$1K |
| 82728 |
|
79 |
75 |
$1K |
| 82550 |
|
74 |
56 |
$979.54 |
| 82553 |
|
51 |
40 |
$880.04 |
| 82962 |
|
85 |
51 |
$814.01 |
| 85651 |
|
157 |
137 |
$733.06 |
| 87147 |
|
64 |
56 |
$679.40 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
231 |
172 |
$629.63 |
| 83550 |
|
73 |
70 |
$599.04 |
| 82607 |
|
61 |
57 |
$591.12 |
| 83540 |
|
89 |
84 |
$530.79 |
| 86140 |
|
61 |
53 |
$501.47 |
| 87088 |
|
90 |
80 |
$419.90 |
| 73030 |
|
14 |
14 |
$368.45 |
| 87205 |
|
113 |
104 |
$344.80 |
| 82150 |
|
16 |
14 |
$332.88 |
| 87040 |
|
15 |
13 |
$288.57 |
| 73630 |
|
13 |
12 |
$242.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
247 |
205 |
$241.46 |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
13 |
12 |
$191.15 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
312 |
288 |
$147.82 |
| 82043 |
|
28 |
27 |
$134.17 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
425 |
372 |
$69.60 |
| 82570 |
|
28 |
27 |
$51.73 |
| A9270 |
Non-covered item or service |
177 |
123 |
$0.00 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
148 |
128 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
31 |
14 |
$0.00 |